

Stem Tronics Announces New Study Results Released in Early Presentation

The findings show that bronchoscopist microwave ablation for certain patients with malignant lung nodules is feasible

SAWARA WARD, FUKUOKA, JAPAN, April 14, 2022 /EINPresswire.com/ -- Stem Tronics, an innovator in the rapidly emerging field of robotic-assisted laparoscopic surgery and a technological leader, is pleased to announce the release of recent clinical data revealing the long-awaited safety and performance outcomes of microwave ablation performed biomicroscopically using the Stem Tronics electromagnetic navigation



bronchoscopy device. The findings were just presented in a late-breaking conference.

"Due to the location of the lesion, comorbidities, and therapeutic side effects, patients with malignant lesions in the lungs frequently have restricted treatment options. The findings of the study look at the potential benefits of more personalized treatment for patients and present a new option for surgeons and clinicians to treat <u>malignant tumors in the lungs</u> in a minimally invasive, localized manner", said Saito Kira, Chief of Research Department at Stem Tronics. To describe the safety and performance of the involved procedures, the study is a prospective, multi-center trial that enrolled several patients from Asia and Europe. All of the patients had a <u>bronchoscopist ablation procedure</u> and were monitored for a determined period of time.

Bronchoscopist microwave ablation is an option for primary and oligometastatic malignant lung nodules (30mm) in patients who decline or are not candidates for both surgery and stereotactic body radiation therapy, according to the findings of the study. All of the participants had acceptable ablation of the lesion after one month of imaging.

To improve diagnosis, optimize treatments, and speed recovery, Stem Tronics continues to take a wide revolutionary approach to the care continuum for the treatment of lung illness.

Stem Tronics will continue to investigate the ablation catheter kit's safety and efficacy as part of a planned investigational device exemption (IDE) study, with the goal of submitting for device approval or clearance at a later date.

About Stem Tronics

Stem-Tronics.com is a pioneer in robotic-assisted, minimally invasive surgery and a technology leader in surgical operations. The robotic surgical system consists of a surgeon-controlled robotic platform with an advanced vision system and innovative equipment for performing standard and complex operating room procedures. Using the Stem Tronics surgical systems, surgeons can perform minimally invasive procedures. Delivering up-to-date technology is only the beginning for Stem Tronics. The company is also dedicated to providing the highest possible client service. In order to ensure that customers gain the most utility from the Stem Tronics systems, the company offers a comprehensive training and education program and first-rate customer support.

Edmund Lowin stem-tronics.com email us here

This press release can be viewed online at: https://www.einpresswire.com/article/568405433

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.